Everything below concerns GLP-1 analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
Secretary of State for Transport Mark Harper announces that regulated train fares in Scotland will rise by 8.7% from April 2024. 22 December – A 78-year-old man has been charged in connection with the death of Marion Hodge of Lockerbie, who was last seen in 1984. 23 December – Multiple warnings for severe weather are issued for the north and west of Scotland following overnight snowfall. 24 December – Humza Yousaf delivers his first Christmas message as first minister, using the address to pay tribute to volunteers and frontline workers. A fleece from the world's first cloned mammal, Dolly the Sheep, is donated to National Museum Scotland. 26 December – A yellow weather warning is issued for heavy rain and high winds ahead of the arrival of Storm Gerrit, expected to cause disruption the following day. 27 December – Storm Gerrit brings widespread disruption to Scotland, with heavy rain, snow and high winds affecting much of the country. 28 December – Around 3,000 properties remain without power following Storm Gerrit. BMA Scotland, the Scottish branch of the British Medical Association, expresses its concerns about staffing levels in the NHS in Scotland, which it says is "dangerously low".
=== Aircraft === C-4, the US Army designation of the Ford Trimotor AEG C.IV, a German World War I reconnaissance aircraft AGO C.IV, a 1917 German reconnaissance aircraft C-4 Academe, the military version of Gulfstream I twin turboprop business aircraft C-4 Argonaut, a Canadair aircraft derived from the Douglas DC-4 Cierva C.4, a 1922 Spanish experimental autogyro DFW C.IV, a 1916 German reconnaissance aircraft Flight Design C4, a four-seat light aircraft Fokker C.IV, a 1923 Dutch two-seat reconnaissance aircraft Rumpler C.IV, a 1917 German single-engine, two-seater reconnaissance biplane
The reduction of activation energy (Ea) increases the fraction of reactant molecules that can overcome this barrier and form the product. An important principle is that since they only reduce energy barriers between products and reactants, enzymes always catalyze reactions in both directions, and cannot drive a reaction forward or affect the equilibrium position – only the speed with which is it achieved. As with other catalysts, the enzyme is not consumed or changed by the reaction (as a substrate is) but is recycled such that a single enzyme performs many rounds of catalysis. Enzymes are often highly specific, i.e. they only act on particular substrates, sometimes only one. Others show group specificity and can act on similar but not identical chemical groups such as peptide bonds. Many enzymes have stereochemical specificity and act on one stereoisomer but not another.
Sources: en.wikipedia.org
In March 2017, Lilly acquired CoLucid Pharmaceuticals for $960 million, obtaining the late clinical-stage migraine therapy candidate lasmiditan. In August 2017, Lilly and Shionogi jointly licensed their product varespladib to Ophirex for Ophirex's novel snakebite treatment program. In May 2018, Lilly acquired Armo Biosciences for $1.6 billion, obtaining the white blood cell-boosting cancer treatment candidate pegilodecakin. Days later, the company announced it would acquire Aurora kinase A inhibitor developer AurKa Pharma, and control over the lead compound, AK-01, for up to $575 million. In January 2019, Lilly announced it would acquire Loxo Oncology for $235 per share, valuing the business at around $8 billion, which significantly expanded the business's oncology offerings. The deal gave Lilly Loxo's oral TRK inhibitor, Vitrakvi (Larotrectinib), LOXO-292, an oral proto-oncogene receptor tyrosine kinase rearranged during transfection (RET) inhibitor, LOXO-305, an oral Bruton's tyrosine kinase (BTK) inhibitor, and LOXO-195, a follow-on TRK inhibitor. In March 2019, the company completed the corporate spin-off of Elanco. In August 2019, Elanco acquired the Bayer animal health business for $7.6 billion. In January 2020, the company announced its acquisition of Dermira for $1.1 billion, gaining control of lebrikizumab, glycopyrronium cloth used in the treatment of hyperhidrosis, and other assets.
=== Classification and identification of bacteria === With the development of instrumental methods for fatty acid analysis, the detection of different fatty acids in bacteria has become a common analytical feature since the 1970s. The fatty acid patterns are often used for taxonomic classification, as related species often have a similar composition of fatty acids in the lipids. The pattern of fatty acid distribution can be used to differentiate between Brucella and Bordetella species. Research results from 2013 show that the occurrence of lactobacillic acid in Brucella canis depends on the geographical origin of the bacterial strains and indicate that only human pathogenic strains contain this fatty acid. Also used to distinguish Weissella species or other lactic acid bacteria
=== Regional chains === MEGA MART, Owner by Nongshim JangbogoFoodMart, JangbogoFoodMart is a regional supermarket chain in Korea, focusing on Gyeongsang Province. Owner by JangbogoFoodMart Co, LTD. TopMart, TopMart is a regional supermarket chain in Korea, focusing on Gyeongsang Province. Owner by SEOWON DISTRIBUTION Co., Ltd. TRIAL, TRIAL is Japan Supermarket Chain Group. South Korea Store Owner by TRIAL Korea Co., Ltd. IGA Segyero Mart
Sources: en.wikipedia.org
=== Intestinal colonization and sepsis === Enterohemorrhagic E. coli (EHEC) and enteropathogenic E. coli (EPEC) are pathogens that rely on OmpT to colonize in the intestine of their host. In response to the presence of E. coli in the gut, the host releases antimicrobial peptides as part of the innate immune response. Since OmpT can break down these antimicrobials and inactivate them, EHEC and EPEC can colonize within the colon or small intestine of the host and lead to serious diarrheal diseases. In the case of sepsis, the host activates the blood clotting system to deposit fibrin and limit the spread of bacteria throughout the blood. However, OmpT can inactivate the tissue factor pathway inhibitor (TFPI), counteracting the host's immune response, and further perpetuating the spread of extraintestinal E. coli infection.
rescue teams were not able to travel to Myanmar because of lack of prompt financing and lack of experienced USAID employees to serve as guides. State Department spokesperson Tammy Bruce said, “I would reject the premise that the sign of success is that we are physically there.” And in fact, a large part of the U.S. effort in previous disasters has been to support local clinics, businesses, and local and international relief organizations. Often, there are secondary crisis(es) from diseases such as cholera which can appear in the days and weeks following a disaster. On April 4, 2025, the U.S. committed an extra $7 million to help with the Myanmar earthquake, thereby increasing its commitment from $2 to $9 million.
Reporter genes are molecular tools widely used in molecular biology, genetics, and biotechnology to study gene function, expression patterns, and regulatory mechanisms. These genes encode proteins that produce easily detectable signals, such as fluorescence, luminescence, or enzymatic activity, allowing researchers to monitor cellular processes in real-time. Reporter genes are often fused to regulatory sequences of genes of interest, enabling scientists to analyze promoter activity, transcriptional regulation, and signal transduction pathways. Common reporter gene systems include green fluorescent protein (GFP), β-galactosidase (lacZ), luciferase, and chloramphenicol acetyltransferase (CAT), each offering distinct advantages depending on the experimental application. Their versatility makes reporter genes invaluable in fields such as drug discovery, gene therapy, and synthetic biology.
=== As biochemical reactors === Synthetic condensates offer a way to probe cellular function and organization with high spatial and temporal control, but can also be used to modify or add functionality to the cell. One way this is accomplished is by modifying the condensate networks to include binding sites for other proteins of interest, thus allowing the condensate to serve as a scaffold for protein release or recruitment. These binding sites can be modified to be sensitive to light activation or small molecule addition, thus giving temporal control over the recruitment of a specific protein of interest. By recruiting specific proteins to condensates, reactants can be concentrated to increase reaction rates or sequestered to inhibit reactivity. More importantly, by spatially organizing the proximity of enzymes in a complex pathway, synthetic condensates can be used to direct the metabolic flux of branched reactions. In an extreme example of using RNA-based synthetic organelle TEARS to organize violacine biosynthesis pathway in E. coli, the side reaction that produces deoxychromoviridans over the desired product deoxyviolacine can be abolished completely by TEARs. In addition to protein recruitment, condensates can also be designed which release proteins in response to certain stimuli. In this case, a protein of interest can be fused to a scaffold protein via a photocleavable linker. Upon irradiation, the linker is broken, and the protein is released from the condensate.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.